INCREASING THE INFORMATION CONTENT OF A COMMERCIAL TISSUE OXIMETER

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 早期识别严重出血是降低战场损伤死亡率和发病率的关键因素。 虽然近红外（NIR）仪器在识别出血方面显示出了希望，但必须解决特定的混杂因素才能在早期出血中可靠。 我们的假设是，这些混杂因素可以消除适当的光组织相互作用建模（频域光子迁移），并通过增加光谱（1000波长）和时间（200毫秒）带宽。 本提案的目的是提供一种紧凑的床旁近红外仪器，能够定量检测早期出血和监测治疗干预。 我们的提案包括（1）领先的生物医学技术公司（ISS，Inc.，尚潘，IL）生产最先进的NIR组织血氧仪，运营生产设施并具有FDA提交经验，以及（2）大学研究团队（Beckman Laser Institute，UC Irvine），组织光学专家具有通过NIR光学方法评估创伤性损伤的经验。 将对现有的ISS血氧计进行修改，以增加解决混杂因素的信息内容。 在第一阶段结束时，我们将提供一种独特的近红外仪器，可用于全面的验证和优化研究（第二阶段）以及随后的商业小型化（第三阶段）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The early recognition of severe hemorrhage is a key factor towards reducing mortality and morbidity from battlefield insults. Although near-infrared (NIR) instruments have shown promise in recognizing hemorrhage, specific confounding factors must be solved to be reliable in early hemorrhage. Our hypothesis is that these confounding factors can be eliminated by proper light-tissue interaction modeling (frequency-domain photon migration), and by increasing spectral (1000 wavelengths) and temporal (200 ms) bandwidth. The objective of this proposal is to provide a compact point-of-care NIR instrument that is capable of quantitatively detecting early hemorrhage and monitoring therapeutic interventions. Our proposal features collaboration between (1) a leading biomedical technology company (ISS, Inc., Champaign, IL) that produces state-of-the-art NIR tissue oximeters, operates production facilities and has FDA submission experience, and (2) a university research team (Beckman Laser Institute, UC Irvine), with tissue optics experts who have experience in the assessment of traumatic injury via NIR optical methods. The existing ISS oximeter will be modified to increase information content that will solve the confounding factors. At the conclusion of Phase I, we will provide a unique NIR instrument that will be available for comprehensive validation and optimization studies (Phase II) and subsequent commercial miniaturization (Phase III).